Project description DEENESFRITPL SiRNA-based Janus kinase inhibition in the treatment of inflammatory bowel diseases Current treatments for inflammatory bowel diseases (IBD) are compromised by low efficacy and tolerability. The EU-funded NEW DEAL project aims to develop novel and radical therapies with improved efficacy and increased safety for all IBD patients, using specific Janus kinase 1 and 3 (JAK1 and JAK3) inhibitors. Previous studies have shown that siRNA-based treatments offer better tolerability, especially in terms of immunogenicity, and the convenience of oral administration. Focusing on the clinical translation of a product based on JAK inhibitors, the project aims to validate inhibition selectivity and safety. Moreover, it will address local delivery of the siRNA to the inflamed gut by the innovative nanostructured lipid carriers with polymeric capsules for protection during transit along the gastrointestinal tract. Show the project objective Hide the project objective Objective Inflammatory bowel diseases (IBD) are the second most common immune-mediated disorders in Europe, affecting more particularly young people. The current therapies, including antibodies, show three main drawbacks: efficacy, tolerability and convenience. NEW DEAL solution will offer radical therapeutic progress for all IBD patients, thanks to the improved efficacy and increased safety of the specific JAK3 inhibition, which has been proven in clinics to be a target of great interest, the better tolerability of siRNA in term of immunogenicity and the good convenience with oral administration. To achieve this challenge, we will address three objectives: i) Specifically inhibit JAK 3 in a highly selective and safer manner by the mean of siRNA carefully designed and validated, ii) Deliver the siRNA therapeutic locally to the inflamed gut, by combining innovative nanostructured lipid carriers enabling their transport across the mucus, the intestinal barrier and the plasma membrane of the target cells, with polymeric capsules for protecting siRNA nanotherapeutics during their transit along the GI tract, thus allowing an oral administration, and iii) Promote the clinical translation and the future industrial transfer of this new clinical product, by addressing manufacturing, safety and efficacy evaluation at the late preclinical stage, to generate a Regulatory Submission Package and a Clinical Development Plan. The NEW DEAL project brings together clinical experts on IBD, leading scientists in nanomedicine, RNAi biology and immunology, innovative SMEs with a strong background in nanosafety, design of capsules and regulatory issues and an established pharma company with historic expertise on gastroenterology medicinal products. If successful, NEW DEAL will open new avenues for siRNA-based therapy in IBD with oral administration. Fields of science medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsmedical and health sciencesclinical medicinegastroenterologyinflammatory bowel diseasenatural sciencesbiological sciencesbiochemistrybiomoleculeslipidsmedical and health sciencesmedical biotechnologynanomedicinemedical and health sciencesbasic medicineimmunologyimmunotherapy Keywords Inflammatory Bowel Diseases siRNA therapeutics JAK inhibition nanostructured lipid carriers polymer capsules colon targeting mucosal barrier industrial scale-up clinical translation Programme(s) H2020-EU.2.1.2. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies Main Programme Topic(s) NMBP-10-2016 - Nanoformulation of biologicals Call for proposal H2020-NMBP-2016-2017 See other projects for this call Sub call H2020-NMBP-2016-two-stage Funding Scheme RIA - Research and Innovation action Coordinator COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES Net EU contribution € 1 915 936,25 Address RUE LEBLANC 25 75015 PARIS 15 France See on map Region Ile-de-France Ile-de-France Paris Activity type Research Organisations Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 1 915 936,25 Participants (13) Sort alphabetically Sort by Net EU contribution Expand all Collapse all EUROPEAN RESEARCH SERVICES GMBH Germany Net EU contribution € 233 337,50 Address HUEFFERSTR. 5 48149 Muenster See on map Region Nordrhein-Westfalen Münster Münster, Kreisfreie Stadt Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 233 337,50 HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH Germany Net EU contribution € 384 965,00 Address INHOFFENSTRASSE 7 38124 Braunschweig See on map Region Niedersachsen Braunschweig Braunschweig, Kreisfreie Stadt Activity type Research Organisations Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 384 965,00 NANOIMMUNOTECH SL Spain Net EU contribution € 506 813,75 Address EDIFICIO CITEXVI C FONTE DAS ABELLE SN CAMPUS UNIVERSITARIO DE VIGO 36310 Vigo Pontevedra See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Noroeste Galicia Pontevedra Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 506 813,75 FUNDACIO DE RECERCA CLINIC BARCELONA-INSTITUT D INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER Spain Net EU contribution € 697 572,50 Address CARRER ROSSELLO 149 08036 Barcelona See on map Region Este Cataluña Barcelona Activity type Research Organisations Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 774 723,75 Third-party Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure. HOSPITAL CLINIC DE BARCELONA Spain Net EU contribution € 77 151,25 Address CALLE VILLARROEL 170 08036 Barcelona See on map Region Este Cataluña Barcelona Activity type Research Organisations Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 77 151,25 PRODIGEST Belgium Net EU contribution € 463 343,75 Address TECHNOLOGIEPARK 3 9052 Gent Zwijnaarde See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Vlaams Gewest Prov. Oost-Vlaanderen Arr. Gent Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 463 343,75 SEPS PHARMA Belgium Net EU contribution € 373 125,00 Address AGORALAAN ABIS 3590 Diepenbeek See on map Region Vlaams Gewest Prov. Limburg (BE) Arr. Hasselt Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 373 125,00 SPARKS & CO Participation ended France Net EU contribution € 43 886,94 Address 66 AVENUE DES CHAMPS ELYSEES ESPACE 41 75008 Paris See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Ile-de-France Ile-de-France Paris Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 43 886,94 INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE France Net EU contribution € 423 560,00 Address RUE DE TOLBIAC 101 75654 Paris See on map Region Ile-de-France Ile-de-France Paris Activity type Research Organisations Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 475 258,75 Third-party Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure. UNIVERSITE GRENOBLE ALPES France Net EU contribution € 51 698,75 Address 621 AVENUE CENTRALE 38058 Grenoble See on map Region Auvergne-Rhône-Alpes Rhône-Alpes Isère Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 51 698,75 LABORATOIRES MAYOLY SPINDLER France Net EU contribution € 448 750,00 Address 6 AVENUE DE L'EUROPE 78400 Chatou See on map Region Ile-de-France Ile-de-France Yvelines Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 448 750,00 ALAN BOYD CONSULTANTS LIMITED United Kingdom Net EU contribution € 188 750,00 Address ELECTRA HOUSE, CREWE BUSINESS PARK CW1 6GL Crewe See on map Region North West (England) Cheshire Cheshire East Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 188 750,00 SCIENSEED SL Spain Net EU contribution € 190 288,06 Address RECADERO 3 BAJO 28002 MADRID See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Comunidad de Madrid Comunidad de Madrid Madrid Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 190 288,06
